![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: OTOA |
Gene summary for OTOA |
![]() |
Gene information | Species | Human | Gene symbol | OTOA | Gene ID | 146183 |
Gene name | otoancorin | |
Gene Alias | CT108 | |
Cytomap | 16p12.2 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q05BM7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
146183 | OTOA | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.71e-05 | 2.40e-01 | -0.0811 |
146183 | OTOA | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.53e-03 | 1.88e-01 | -0.1207 |
146183 | OTOA | HTA11_696_2000001011 | Human | Colorectum | AD | 3.19e-14 | 2.54e-01 | -0.1464 |
146183 | OTOA | HTA11_866_2000001011 | Human | Colorectum | AD | 2.51e-02 | 1.08e-01 | -0.1001 |
146183 | OTOA | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.19e-06 | 2.05e-01 | -0.059 |
146183 | OTOA | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.14e-02 | 2.48e-01 | -0.1706 |
146183 | OTOA | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.98e-02 | 1.68e-01 | 0.0588 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031589 | Colorectum | AD | cell-substrate adhesion | 116/3918 | 363/18723 | 4.68e-07 | 1.76e-05 | 116 |
GO:0007160 | Colorectum | AD | cell-matrix adhesion | 75/3918 | 233/18723 | 3.56e-05 | 6.45e-04 | 75 |
GO:00315891 | Colorectum | SER | cell-substrate adhesion | 86/2897 | 363/18723 | 2.36e-05 | 6.64e-04 | 86 |
GO:00071601 | Colorectum | SER | cell-matrix adhesion | 53/2897 | 233/18723 | 2.10e-03 | 2.06e-02 | 53 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OTOA | SNV | Missense_Mutation | novel | c.3389T>G | p.Leu1130Arg | p.L1130R | Q7RTW8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-A2-A3XX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
OTOA | SNV | Missense_Mutation | novel | c.406N>C | p.Lys136Gln | p.K136Q | Q7RTW8 | protein_coding | tolerated(0.46) | benign(0.086) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
OTOA | SNV | Missense_Mutation | novel | c.2855N>C | p.Leu952Pro | p.L952P | Q7RTW8 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
OTOA | SNV | Missense_Mutation | novel | c.608A>G | p.Asp203Gly | p.D203G | Q7RTW8 | protein_coding | tolerated(0.21) | benign(0.006) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OTOA | SNV | Missense_Mutation | novel | c.679T>G | p.Ser227Ala | p.S227A | Q7RTW8 | protein_coding | tolerated(0.51) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OTOA | SNV | Missense_Mutation | rs141037250 | c.1499C>T | p.Ala500Val | p.A500V | Q7RTW8 | protein_coding | tolerated(0.05) | benign(0.006) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OTOA | SNV | Missense_Mutation | rs548486726 | c.1073N>T | p.His358Leu | p.H358L | Q7RTW8 | protein_coding | deleterious(0.03) | benign(0.079) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
OTOA | SNV | Missense_Mutation | novel | c.1082N>T | p.Gly361Val | p.G361V | Q7RTW8 | protein_coding | tolerated(0.08) | probably_damaging(1) | TCGA-AR-A2LK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | PD |
OTOA | SNV | Missense_Mutation | c.1603A>G | p.Lys535Glu | p.K535E | Q7RTW8 | protein_coding | tolerated(0.14) | possibly_damaging(0.706) | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
OTOA | SNV | Missense_Mutation | c.1436N>G | p.Ser479Cys | p.S479C | Q7RTW8 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |